MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals shares are trading higher following the announcement of new preclinical study results for its novel oral ketamine analog, Ketamir-2.
July 22, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals shares are experiencing an upward trend after the company announced positive preclinical study results for its novel oral ketamine analog, Ketamir-2.
The announcement of positive preclinical results for Ketamir-2 is likely to boost investor confidence in MIRA Pharmaceuticals, leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100